EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

European Patent Office deals blow to pharma companies in dismissing their attempts to reinstate patents covering diabetes and obesity treatments | Inhibrx antibody patent upheld as Gilead subsidiary appeal is rejected.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Europe

Novo secures website blocking to tackle fake weight-loss drugs

25 June 2026 A UK judge extends a blocking order aimed at ISPs including BT, EE, and Sky, allowing the maker of Ozempic and Wegovy to add infringing sites that sell counterfeits without returning to court.

Europe

UPC hands Occlutech second win against Chinese medtech company in a month

19 June 2026 The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.

Europe

Exclusive: ‘Cultural differences are an asset’ at the UPC

16 June 2026 In the second of a series of interviews with women judges at the pan-European court, Ulrike Voß talks to Sarah Speight about her career, her views on the court so far, and how more women could be encouraged to join the judiciary.

More features

Pfizer’s US Paxlovid patent fight turns on a single error

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

Novo secures website blocking to tackle fake weight-loss drugs

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

Cooley Asia transactions duo make rival firm move

Insilico lands potential $2.5bn AI biotech partnership

‘Blatant imitation’: Indian court blocks copycat pharma branding

UPC hands Occlutech second win against Chinese medtech company in a month

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

More on this story

Editor's picks

Editor's picks

More features